Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements

European Journal of Clinical Pharmacology

Volumn 66, Issue 3, 2010, Pages 253-260

  Cadamuro, Janne ^a   Dieplinger, Benjamin ^b   Felder, Thomas ^a   Kedenko, Igor ^a   Mueller, Thomas ^b   Haltmayer, Meinhard ^b   Patsch, Wolfgang ^a   Oberkofler, Hannes ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Acenocoumarol; Pharmacogenetics; Phenprocoumon; Single nucleotide polymorphisms

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; APOLIPOPROTEIN E; CYTOCHROME P450 2C9; CYTOSINE; MENADIONE EPOXIDE; PHENPROCOUMON; THYMINE; VITAMIN K DEPENDENT CARBOXYLASE; VITAMIN K GROUP; CALCIUM BINDING PROTEIN; CALU PROTEIN, HUMAN; CYP2C9 PROTEIN, HUMAN; GLUTAMYL CARBOXYLASE; LIGASE; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; COHORT ANALYSIS; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HEREDITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; CHI SQUARE DISTRIBUTION; GENE FREQUENCY; GENETICS; HETEROZYGOTE; HOMOZYGOTE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHENOTYPE; REGRESSION ANALYSIS;

ACENOCOUMAROL; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; APOLIPOPROTEINS E; ARYL HYDROCARBON HYDROXYLASES; CALCIUM-BINDING PROTEINS; CARBON-CARBON LIGASES; CHI-SQUARE DISTRIBUTION; FEMALE; GENE FREQUENCY; GENOTYPE; HEMORRHAGE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHENOTYPE; PHENPROCOUMON; POLYMORPHISM, SINGLE NUCLEOTIDE; REGRESSION ANALYSIS; YOUNG ADULT;

EID: 77951931834     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0768-7     Document Type: Article

References (49)

1. Cannegieter SC, Torn M, Rosendaal FR (1999) Oral anticoagulant treatment in patients with mechanical heart valves: how to reduce the risk of thromboembolic and bleeding complications. J Intern Med 245(4):369-374
2. D'Andrea G, D'Ambrosio R, Margaglione M (2008) Oral anticoagulants: pharmacogenetics relationship between genetic and non-genetic factors. Blood Rev 22(3):127-140
3. He M, Korzekwa KR, Jones JP, Rettie AE, Trager WF (1999) Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Arch Biochem Biophys 372 (1):16-28
4. Takanashi K, Tainaka H, Kobayashi K et al (2000) CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 10(2):95-104
5. Taube J, Halsall D, Baglin T (2000) Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96 (5):1816-1819
6. Lindh JD, Holm L, Andersson ML, Rane A (2008) Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis. Eur J Clin Pharmacol 65(4):365-375
7. Higashi MK, Veenstra DL, Kondo LM et al (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287(13):1690-1698
8. Aithal GP, Day CP, Kesteven PJ, Daly AK (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353 (9154):717-719
9. Hirsh J, Dalen J, Anderson DR et al (2001) Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119(1 Suppl):8S-21S
10. Wu SM, Stafford DW, Frazier LD et al (1997) Genomic sequence and transcription start site for the human gamma-glutamyl carboxylase. Blood 89(11):4058-4062
11. Li T, Chang CY, Jin DY et al (2004) Identification of the gene for vitamin K epoxide reductase. Nature 427(6974):541-544
12. Rost S, Fregin A, Ivaskevicius V et al (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427(6974):537-541
13. Wang D, Chen H, Momary KM et al (2008) Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 112(4):1013-1021
14. Geisen C, Watzka M, Sittinger K et al (2005) VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 94(4):773-779
15. Reitsma PH, van der Heijden JF, Groot AP et al (2005) A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med 2(10):e312
16. Wadelius M, Chen LY, Downes K et al (2005) Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 5(4):262-270
17. Gonzalez-Conejero R, Corral J, Roldan Vet al (2007) The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol. J Thromb Haemost 5(8):1701-1706
18. Wajih N, Sane DC, Hutson SM, Wallin R (2004) The inhibitory effect of calumenin on the vitamin K-dependent gammacarboxylation system. Characterization of the system in normal and warfarin-resistant rats. J Biol Chem 279(24):25276-25283
19. Khan T, Wynne H, Wood P et al (2004) Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin. Br J Haematol 124(3):348-354
20. Lamon-Fava S, Sadowski JA, Davidson KW et al (1998) Plasma lipoproteins as carriers of phylloquinone (vitamin K1) in humans. Am J Clin Nutr 67(6):1226-1231
21. Saupe J, Shearer MJ, Kohlmeier M (1993) Phylloquinone transport and its influence on gamma-carboxyglutamate residues of osteocalcin in patients on maintenance hemodialysis. Am J Clin Nutr 58(2):204-208
22. Kimmel SE, Christie J, Kealey C et al (2008) Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics J 8(1):53-60
23. Klein TE, Altman RB, Eriksson N et al. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360(8):753-764
24. Baxter K (ed) (2007) Stockley's drug interactions: a source book of interactions, their mechanisms, clinical importance and management, 8 ed. Pharmaceutical Press, London
25. Lacy CF, Armstrong LL, Goldman MP, Lance LL (eds) (2009) Drug information handbook: a comprehensive resource for all clinicians and healthcare professionals, 18th ed. Lexi-Comp, Hudson, OH
26. Oberkofler H, Linnemayr V, Weitgasser R et al (2004) Complex haplotypes of the PGC-1alpha gene are associated with carbohydrate metabolism and type 2 diabetes. Diabetes 53(5):1385-1393
27. Au N, Rettie AE (2008) Pharmacogenomics of 4-hydroxycoumarin anticoagulants. Drug Metab Rev 40(2):355-375
28. Ufer M (2005) Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 44(12):1227-1246
29. Bodin L, Verstuyft C, Tregouet DA et al (2005) Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106(1):135-140
30. Qazim B, Stollberger C, Krugluger Wet al (2008) Dependency of phenprocoumon dosage on polymorphisms in the VKORC1 and CYP2C9 genes. J Thromb Thrombolysis 28:211-214
31. Schalekamp T, Brasse BP, Roijers JF et al (2007) VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin Pharmacol Ther 81(2):185-193
32. D'Andrea G, D'Ambrosio RL, Di Perna P et al (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105(2):645-649
33. Rieder MJ, Reiner AP, Gage BF et al (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352(22):2285-2293
34. Thijssen HH, Flinois JP, Beaune PH (2000) Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos 28 (11):1284-1290
35. Li C, Schwarz UI, Ritchie MD et al. (2008) Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood 113:3925-3930
36. Ufer M, Kammerer B, Kahlich R et al (2004) Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo. Xenobiotica 34(9):847-859
37. Kirchheiner J, Ufer M, Walter EC et al (2004) Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and Sphenprocoumon in healthy volunteers. Pharmacogenetics 14(1):19-26 (Pubitemid 38183958)
38. Visser LE, van Schaik RH, van Vliet M et al (2004) The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost 92(1):61-66
39. Hummers-Pradier E, Hess S, Adham IM et al (2003) Determination of bleeding risk using genetic markers in patients taking phenprocoumon. Eur J Clin Pharmacol 59(3):213-219
40. Schalekamp T, Oosterhof M, van Meegen E et al (2004) Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. Clin Pharmacol Ther 76(5):409-417
41. Caldwell MD, Awad T, Johnson JA et al (2008) CYP4F2 genetic variant alters required warfarin dose. Blood 111(8):4106-4112
42. Vecsler M, Loebstein R, Almog S et al (2006) Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost 95(2):205-211
43. Wadelius M, Chen LY, Eriksson N et al (2007) Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 121(1):23-34
44. Kimura R, Miyashita K, Kokubo Y et al (2007) Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 120(2):181-186
45. Pudota BN, Hommema EL, Hallgren KW et al (2001) Identification of sequences within the gamma-carboxylase that represent a novel contact site with vitamin K-dependent proteins and that are required for activity. J Biol Chem 276(50):46878-46886
46. Visser LE, Trienekens PH, De Smet PA et al (2005) Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants. Pharmacogenet Genomics 15(2):69-74
47. Cooper GM, Johnson JA, Langaee TY et al (2008) A genomewide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112(4):1022-1027
48. Teichert M, Eijgelsheim M, Rivadeneira F et al (2009) A genomewide association study of acenocoumarol maintenance dosage. Hum Mol Genet 18(19):3758-3768
49. Wadelius M, Chen LY, Lindh JD et al (2009) The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113(4):784-792